Search Results - "Lopes Pegna, A"

Dose exposure in the ITALUNG trial of lung cancer screening with low-dose CT by MASCALCHI, M, MAZZONI, L. N, PACI, E, FALCHINI, M, BELLI, G, PICOZZI, G, MERLINI, V, VELLA, A, DICIOTTI, S, FALASCHI, F, LOPES PEGNA, A

“…Few data are available on the effective dose received by participants in lung cancer screening programmes with low-dose CT (LDCT). We report the collective…”
Get full text

Increased dose-intensity of gemcitabine in advanced non small cell lung cancer (NSCLC): a multicenter phase II study in elderly patients from the “polmone toscano group” (POLTO) by Tibaldi, C., Ricci, S., Russo, F., Bernardini, I., Galli, L., Chioni, A., Orlandini, C., Grosso, A.M., Pegna, A. Lopes, Fabbri, A., Innocenti, F., Ferrari, K., Tognarini, L., Conte, P.F., Falcone, A.

“…Gemcitabine is usually administered at a planned dose-intensity (DI) from 750 to 800 mg/m 2/week. Preclinical data have suggested a possible dose–response…”
Get full text

Gender differences in non-small cell lung cancer: A population-based study by Caldarella, A, Crocetti, E, Comin, C.E, Janni, A, Pegna, A. Lopes, Paci, E

“…Abstract Background A retrospective study including all patients with non-small cell lung cancer carcinoma in a population-based registry was performed to…”
Get full text

Gemcitabine monotherapy in elderly patients with advanced non-small cell lung cancer: A multicenter phase II study by Ricci, S, Antonuzzo, A, Galli, L, Tibaldi, C, Bertuccelli, M, Lopes Pegna, A, Petruzzelli, S, Algeri, R, Bonifazi, V, Fioretto, M.L, Orlandini, C, Conte, P.F

“…Background: This trial investigated the activity and toxicity of gemcitabine in previously untreated elderly (>70 years) patients with advanced (stage IIIB-IV)…”
Get full text

C25 HEALTH EFFECTS OF SMOKING AND BIOMASS FUEL: Short Term Longitudinal Evaluation Of Smoking-Related Emphysema: Analisys From Italung-CT Study by Carrozzi, L, Conti, B, Aquilini, F, Pistelli, F, Romei, C, Tavanti, L M, Viegi, G, Palla, A, Pegna, A Lopes, Paci, E, Falaschi, F

Get full text

Mycobacterium xenopi Isolation from Clinical Specimens in the Florence Area: Review of 46 Cases by Tortoli, E., Simonetti, M. T., Labardi, C., Pegna, A. Lopes, Meli, E., Stanflin, N., Susini, S.

“…The occurrence of Mycobacterium xenopi (MX) isolates is not homogeneous in various geographic zones. In the Florence area, between 1975-1989, strains of MX…”
Get full text

P-271 ITALUNG_CT screening for lung cancer: Preliminary results by Ronchi, M., Cordopatri, G., De Francisci, A., Innocent, F., Janni, A., Mascalchi, M., Masi, A., Paci, E., Picozzi, G., Lopes Pegna, A.

Get full text

A randomized study comparing two different schedules of administration of cisplatin in combination with gemcitabine in advanced nonsmall cell lung carcinoma by Ricci, Sergio, Antonuzzo, Andrea, Galli, Luca, Tibaldi, Carmelo, Bertuccelli, Maurizio, Lopes Pegna, Andrea, Petruzzelli, Stefano, Bonifazi, Vittorio, Orlandini, Cinzia, Franco Conte, Pier

“…BACKGROUND This randomized trial was designed to investigate the feasibility, toxicity, and activity of two different schedules of gemcitabine plus cisplatin…”
Get full text

Chemotherapy with gemcitabine in elderly patients (or in patients not candidate for a cisplatin regimen) with advanced NSCLC: a multicenter phase II study by Tibaldi, C., Ricci, S., Russo, F., Chioni, A., Iannopollo, M., Galli, L., Grosso, A.M., Lopes Pegna, A., Puccinelli, P., Fabbri, A.

Get full text

Cisplatin and etoposide combination in the treatment of bronchogenic carcinoma by Mazzei, T, Marino, C, Nozzoli, F, Lopes-Pegna, A, Righi, R, Santomaggio, C, Lamanna, S, Periti, P

“…The authors investigated the activity of a combination of DDP 80 mg/m2 i.v. followed by VP16 50 mg/m2 on days 2-5 in bronchogenic carcinoma. Twenty-seven…”
Get more information

Multicentric randomized phase II study with gemcitabine (GEM) plus cisplatin (CDDP) in patients with stage IIIB-IV NSCLC by Ricci, S, Antonuzzo, A, Galli, L, Algeri, R, Bonifazi, V, Andrei, A, Petruzzelli, S, Dupré, C, Lopes Pegna, A, Conte, PF

Get full text

Gemcitabine monotherapy in the elderly patient with advanced non-small cell lung cancer (NSCLC): preliminary results of a tuscany multicentric phase II study by Antonuzzo, A, Galli, L, Ricci, S, Tibaldi, C, Bertuccelli, M, Petruzzelli, S, Tavanti, L, Fioretto, ML, Giallombardo, A, Algeri, R, Andrei, A, Lopes Pegna, A, Conte, PF

Get full text

Glycosaminoglycans in pleural effusions. Preliminary results by Catalani, C, Pasquali, F, Lopes Pegna, A, Labardi, C, Perri, F

“…Distinction between benign and malignant pleural effusions is often a very difficult problem. Glycosaminoglycans play an important role in cellular…”
Get more information

Multiple primary malignancies. A case with 4 primary tumors by Godi, F, Lopes Pegna, A, Nozzoli, F

Get more information

Electrocardiographic behavior in pulmonary thromboembolism by Lapi, P R, Schiavetti, A, Lopes-Pegna, A, Labardi, C

Get more information

HLA and familial scleroderma by Matucci-Cerinic, M, Lombardi, A, Lopes-Pegna, A, Menicucci, A, Lotti, T

Get more information